Výsledky vyhledávání - "A.A. Verstraeten"

The quality of intrapartum fetal heart rate monitoring

Autor: G. J. Colenbrander, P.C.A.M. Bakker, H.P. van Geijn, A.A. Verstraeten

Publikováno v: European Journal of Obstetrics and Gynecology and Reproductive Biology, 116(1), 22-27. Elsevier Ireland Ltd
Bakker, P C A M, Colenbrander, G J, Verstraeten, A A & Van Geijn, H P 2004, ' The quality of intrapartum fetal heart rate monitoring ', European Journal of Obstetrics and Gynecology and Reproductive Biology, vol. 116, no. 1, pp. 22-27 . https://doi.org/10.1016/j.ejogrb.2004.01.001

Objective : To determine the quality of fetal heart rate (FHR) recordings during the first and second stage of labor by quantifying the amount of fetal signal loss in relation to the method of monitoring: external ultrasound or directly via a scalp e

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::17c35b00a5f84ecb2c0396c5a9e6977e
https://doi.org/10.1016/j.ejogrb.2004.01.001

Zobrazit plný text záznamu

Reactivity of natural and induced human antibodies to MUC1 mucin with MUC1 peptides andn-acetylgalactosamine (GalNAc) peptides

Autor: Michael R. Price, F.G.M. Snijdewint, A.A. Verstraeten, Kees van Uffelen, Peter Kenemans, J. Hilgers, Celso A. Reis, Eftichia Petrakou, Philip O. Livingston, Dick J. Schol, Silvia von Mensdorff-Pouilly, Gerard J. van Kamp

Publikováno v: International Journal of Cancer. 86:702-712

Antibodies (Abs) to MUC1 occur naturally in both healthy subjects and cancer patients and can be induced by MUC1 peptide vaccination. We compared the specificity of natural and induced MUC1 Abs with the objective of defining an effective MUC1 vaccine

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ecff8b58bb3c98366ac1915c442ad82b
https://doi.org/10.1002/(sici)1097-0215(20000601)86:5<702::aid-ijc16>3.0.co

Zobrazit plný text záznamu

Estimation of Probability of Malignancy Using a Logistic Model Combining Physical Examination, Ultrasound, Serum CA 125, and Serum CA 72-4 in Postmenopausal Women with a Pelvic Mass: An International Multicenter Study

Autor: G. Crombach, H. Caffier, Manfred Kaufmann, R. Kreienberg, Christof Sohn, P. Kenemans, Volker Möbus, A.A. Verstraeten, P. Kristen, E.M.J. Schutter

Publikováno v: Gynecologic Oncology. 69:56-63

Background. To assess the differential diagnostic potential of physical examination, ultrasound, the serum CA 125 assay, and serum CA 72-4 assay, and the contribution of each parameter to a logistic model predicting the probability of malignancy in p

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::49766984f5075fd650317bb185238dbe
https://doi.org/10.1006/gyno.1998.4942

Zobrazit plný text záznamu

Humoral immune response to polymorphic epithelial mucin (MUC-1) in patients with benign and malignant breast tumours

Autor: G. J. Van Kamp, Sergey V. Litvinov, S. von Mensdorff-Pouilly, M. M. Gourevitch, Sybren L. Meijer, Jan B. Vermorken, A.A. Verstraeten, Peter Kenemans, J. Hilgers

Publikováno v: European Journal of Cancer. 32:1325-1331

To investigate the clinical significance of an immune response to the MUC-1 encoded polymorphic epithelial mucin (PEM) breast cancer, circulating immune complexes containing PEM (PEM.CIC) were measured in sera from 96 healthy women, in pretreatment s

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7443eb724da1f9944a7850118b82eacc
https://doi.org/10.1016/0959-8049(96)00048-2

Zobrazit plný text záznamu

Mucin-Like Carcinoma-Associated Antigen Serum Levels in Patients with Adenocarcinomas Originating from Ovary, Breast and Colon

Autor: A.A. Verstraeten, G.J. van Kamp, P. Kenemans, J.M. Zuetenhorst, G.G. Bon, R Verheijen

Publikováno v: Gynecologic and Obstetric Investigation. 42:58-62

The mucin-like carcinoma-associated antigen (MCA) enzyme immunoassay was tested in 962 healthy controls. MCA levels were compared with CA 125 in 70 patients with benign and 76 with malignant ovarian tumors. In addition MCA was compared with CA 15.3 i

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0acd5ff13b7d9f198a42d14d59017d03
https://doi.org/10.1159/000291890

Zobrazit plný text záznamu

Polymorphic epithelial mucin (MUC-1)-containing circulating immune complexes in carcinoma patients

Autor: G. J. Van Kamp, Sergey V. Litvinov, A.A. Verstraeten, J. Hilgers, P. Kenemans, S. von Mensdorff-Pouilly, M. M. Gourevitch

Publikováno v: British Journal of Cancer

Circulating immune complexes (CICs) containing polymorphic epithelial mucin (PEM/MUC-1) were found in sera of 24.5% of 151 primary breast carcinoma patients and 18-21.4% of patients with advanced ovarian (n = 56) and breast carcinomas (n = 61), 37% o

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::689950de862552e735767693e1415bd4
https://doi.org/10.1038/bjc.1995.436

Zobrazit plný text záznamu

The Second Generation CA125 Assays

Autor: A.A. Verstraeten, G. J. Van Kamp, P. Kenemans, S. von Mensdorff-Pouilly

Publikováno v: Annals of Medicine. 27:107-113

Optimal management of ovarian cancer patients can only be provided using the CA 125 serum test for treatment monitoring, early prediction of outcome and early detection of recurrence. The newly introduced second generation CA 125 assays, the Centocor

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9151f11bf00e9bd0f8677f8c1b3e9b54
https://doi.org/10.3109/07853899509031945

Zobrazit plný text záznamu

Expression of tenascin, biglycan and decorin in disorders of keratinization

Autor: Peter M. Steijlen, H. Trauper, H. Kressh, I.M.J.J. Vlijmen, A.A. Verstraeten, E. Maessen, J. Schalkwijk

Publikováno v: British Journal of Dermatology. 130:564-568

Summary The distribution of three (recently discovered) extracellular matrix components (tenascin, biglycan and decorin) was studied in normal adult human skin and in a number of monogenic disorders of keratinization, using immunohistology. The expre

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4fdafb46934d925e472349416eb01437
https://doi.org/10.1111/j.1365-2133.1994.tb13100.x

Zobrazit plný text záznamu

Discordant serum CA 125 values in commercial immunoassays

Autor: P. Kenemans, G.J. van Kamp, A.A. Verstraeten

Publikováno v: European Journal of Obstetrics & Gynecology and Reproductive Biology. 49:99-103

The CA 125 assay is from a clinical point of view very well suited to monitor ovarian cancer patients. Although most commercial assay systems include as standards CA 125 preparations derived from the OVCA 433 cell line, the various assay configuratio

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fe3c3198fb9f2afd9b2c5f684126fc6a
https://doi.org/10.1016/0028-2243(93)90132-v

Zobrazit plný text záznamu

CA 125 half-life in ovarian cancer: a multivariate survival analysis

Autor: G.G. Bon, C Schijf, Jan B. Vermorken, CA Yedema, J. Hilgers, Feja J. Voorhorst, A.A. Verstraeten, P. Kenemans, Louk V.A.M. Beex

Publikováno v: British Journal of Cancer

Serum CA 125 regression after cytoreductive surgery and during the first three courses of chemotherapy was studied in 60 ovarian cancer patients and compared to known prognostic factors. Various methods reported in the literature to calculate a CA 12

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::04b8e8eaf3f605cd2fa1fec1bb5e99e3
http://europepmc.org/articles/PMC1968500

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání